This CME program will provide clinicians with an update regarding the safety and efficacy of JAK inhibitor therapeutics for the treatment of atopic dermatitis. The expert faculty, led by Dr. Lawrence F. Eichenfield, will first outline current clinical trial data for JAK-1 inhibitor therapeutics in atopic dermatitis (AD), encompassing topics such as difficulties living with AD and the unmet needs for patients. Following, further data regarding JAK inhibitors, and the duality of immunomodulation versus immunosuppression will be presented from the allergist’s perspective, and clinical relevance debated among the panel. To conclude, the faculty will analyze data presented at the American Academy of Dermatology 2022 Annual Meeting in a discussion-based format. Upon completion of this activity, learners will be better equipped to treat and manage their patients with atopic dermatitis.
Dermatologists, allergists, and other healthcare professionals involved in the management of patients with atopic dermatitis
I. Review of JAK Inhibitor Therapeutics and Analysis of Unmet Needs for Patients with Atopic Dermatitis
II. New and Emerging Data, Including Data Presented at AAD 2022
III. Updating Risk/Benefit Profile, COVID-19 and JAK Inhibitors of New Trial Data & Therapeutics
- Review and analyze new and emerging data for advanced therapies to treat patients with atopic dermatitis, including data presented at AAAAI 2022 and AAD 2022
- Apply information from AAAAI 2022 and AAD 2022 to update risk/benefit profiles of JAK inhibitor therapeutics for atopic dermatitis
- Understand the role of COVID-19 vaccination in the care of patients with atopic dermatitis, especially those receiving treatment with JAK inhibitors and other immunosuppressive agents
Lawrence F. Eichenfield, MD (Program Chair)
Professor of Dermatology and Pediatrics
Vice Chair, Department of Dermatology
Chief, Pediatric and Adolescent Dermatology
University of California, San Diego
Rady Children’s Hospital
San Diego, CA
Bob Geng, MD
Assistant Professor of Pediatrics and Medicine
Co-Director of Rady Children’s Hospital Severe Asthma Program
Allergy/Immunology Director of the Multidisciplinary Atopic Dermatitis Program (MADP)
Divisions of Adult and Pediatric Allergy and Immunology
University of California, San Diego
San Diego, CA
Disclosures of Relevant Financial Relationships
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships relating to the topics of this educational activity. Any relevant financial relationships are mitigated via a content review by planning committee members and faculty with no relevant financial relationships.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
|Faculty||Relationship Identified With:|
|Lawrence F. Eichenfield, MD (Program Chair)||Consultant/Advisor: AbbVie Inc.; Almirall; Amgen Inc; Arcutis Biotherapeutics; Arena Pharmaceuticals; ASLAN Pharmaceuticals; Castle Creek Biosciences, Inc.; DERMATA THERAPEUTICS, INC.; Dermavant Sciences, Inc.; Eli Lilly and Company; Forte Biosciences, Inc.; Galderma; Ichinos Sciences; Incyte Corporation; Janssen Global Services, LLC; LEO Pharma A/S; Novartis; Ortho Dermatologics; Otsuka America Pharmaceutical, Inc; Pfizer Inc.; Regeneron Pharmaceuticals Inc.; Sanofi Genzyme; Union Therapeutics
Grant/Research Support: AbbVie Inc.; Arcutis Biotherapeutics; Dermavant Sciences, Inc.; Galderma; Incyte Corporation; Ortho Dermatologics; Pfizer Inc.; Verrica Pharmaceuticals
Speaker’s Bureau: LEO Pharma A/S; Novartis; Incyte Corporation; Pfizer Inc.; Regeneron Pharmaceuticals Inc.; Sanofi Genzyme
Stockholder: DERMATA THERAPEUTICS, INC.; Forte Biosciences, Inc.; Verrica Pharmaceuticals
|Bob Geng, MD
|Consultant/Advisor: Galderma; Pfizer Inc.; Regeneron Pharmaceuticals Inc.; Sanofi Genzyme
Grant/Research Support: Regeneron Pharmaceuticals Inc.; Sanofi Genzyme
Speaker’s Bureau: Regeneron Pharmaceuticals Inc.; Sanofi Genzyme
|Eric Simpson, MD, MCR||Consultant/Advisor: AbbVie Inc.; Amgen Inc.; Arena Pharmaceuticals; ASLAN Pharmaceuticals; BenevolentAI; BiomX; Bluefin Biomedicine; Boehringer Ingelheim International GmbH; Boston Consulting Group; Collective Acumen LLC; Coronado Biosciences; Corevita Health Inc.; Dermira, Inc.; Eli Lilly and Company; Evidera; Excerpta Medica; Forte Biosciences, Inc.; Galderma; GlaxoSmithKline; Incyte Corporation; Janssen Global Services, LLC; Kyowa Kirin Co., Ltd; LEO Pharma A/S; Medscape, Inc; Merck & Co., Inc.; Novartis; Ortho Dermatologics; Pfizer Inc.; Physicians World, LLC; Pierre Fabre group; Regeneron Pharmaceuticals Inc.; Roivant Sciences Ltd; Sanofi Genzyme; SPARC; Trevi Therapeutics; Valeant Pharmaceuticals; WebMD LLC
Grant/Research Support: AbbVie Inc.; Amgen Inc; Arcutis Biotherapeutics; ASLAN Pharmaceuticals; Corevita Health Inc.; Dermira, Inc.; Eli Lilly and Company; Incyte Corporation; Kyowa Kirin Co., Ltd; LEO Pharma A/S; Novartis; Pfizer Inc.; Regeneron Pharmaceuticals Inc.; Sanofi Genzyme; SPARC; Trevi Therapeutics
Speaker’s Bureau: AbbVie Inc.; Eli Lilly and Company; LEO Pharma A/S; Medscape, Inc; Pfizer Inc.; Regeneron Pharmaceuticals Inc.; Sanofi Genzyme
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole McMenamin; Chelsey Benedek and Emma Boring hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council forPharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this live material for a maximum of 1.75 AMA PRA Category 1 Credits TM.
Clinicians should only claim credit commensurate with the extent of their participation.
This activity has been supported by independent educational grants from Incyte Corporation and Pfizer Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME, Incyte Corporation and Pfizer Inc. do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 50% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].